Quince Therapeutics News

This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

BenzingaOct 29 20:11

Quince Therapeutics Price Target Announced at $11.00/Share by Rodman & Renshaw

Dow JonesOct 29 19:44 · Ratings

Quince Therapeutics Initiated at Buy by Rodman & Renshaw

Dow JonesOct 29 19:44 · Ratings

12 Health Care Stocks Moving In Thursday's After-Market Session

BenzingaOct 25 04:31

EF Hutton Initiates Coverage On Quince Therapeutics With Buy Rating, Announces Price Target of $12

BenzingaOct 22 19:14 · Ratings

Quince Therapeutics Analyst Ratings

BenzingaOct 22 19:12 · Ratings

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

BusinesswireSep 4 04:05

Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

BenzingaAug 16 18:55

Express News | Quince Therapeutics: Expects Potential Nda Submission to FDA & Marketing Authorization Application Submission to EMA in 2026

BreakingsAug 15 19:02

Express News | Quince Therapeutics: Expects to Report Topline Results in Q4 of 2025

BreakingsAug 15 19:01

Express News | Quince Therapeutics Announces the Lancet Neurology Publication of Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (a-T)

BreakingsAug 15 19:00

Express News | Quince Therapeutics- Qtrly Reported a Net Loss of $27.7 Mln, or a Net Loss of $0.64 per Basic and Diluted Share

BreakingsAug 14 04:20

Express News | Quince Therapeutics - Strong Cash Position Expected to Provide Sufficient Operating Runway Into 2026

BreakingsAug 14 04:19

Quince Therapeutics | 10-Q: Q2 2024 Earnings Report

SECAug 14 04:17 · Announcements

Express News | Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

BreakingsAug 14 04:05

Quince Therapeutics Doses First Subject in Ataxia-Telangiectasia Trial

Yahoo FinanceJun 26 19:13

Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026

BenzingaJun 25 19:09

Express News | Quince Expects Phase 3 Neat Results H2 2025

BreakingsJun 25 19:01

Express News | Quince Therapeutics Initiates Phase 3 Trial of Erydex

BreakingsJun 25 19:01

Express News | Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia

BreakingsJun 25 19:00